Tropical Medicine & Clinical Parasitology, Infectious Diseases Department, Ramón y Cajal Hospital, Madrid, Spain.
J Travel Med. 2009 Nov-Dec;16(6):395-401. doi: 10.1111/j.1708-8305.2009.00341.x.
Leishmaniasis is endemic in many countries. The existence of different species combined with host factors may condition clinical presentation, treatment options, and disease outcome. In an endemic country, a predominance of certain species and presentations may be expected, whereas from the perspective of a tropical medicine referral unit a wider variety of cases from diverse geographical areas may be observed.
Retrospective study of imported leishmaniasis cases diagnosed at a Tropical Medicine referral unit in Spain, during the period of January 1995 to June 2008.
In total, 18 cases were diagnosed: 12 cutaneous leishmaniasis (CL), 4 mucocutaneous leishmaniasis (ML), and 2 visceral leishmaniasis (VL) cases. Two patients were immunosuppressed. The majority of CL cases (9/12) occurring in travelers were acquired in New World countries and were treated with pentavalent antimonials. Three ML cases were acquired in the New World, two received initial treatment with pentavalent antimonials and two with liposomal amphotericin B (LAmB). For all four ML cases, a change in drug choice and multiple treatment courses were necessary, and one remained refractory to treatment. Both VL cases were acquired in Africa and responded well to LAmB treatment.
The management of leishmaniasis in non-endemic countries is still a challenge for physicians. With the variety of cases presented, both in immigrants and travelers from different geographical areas, this series illustrates the great diversity of imported leishmaniasis in terms of presentation, treatment options, and outcome. We consider this entity is becoming increasingly more frequent and clinicians should be aware of strategies for its correct management.
利什曼病在许多国家流行。不同物种的存在以及宿主因素可能影响临床表现、治疗选择和疾病结局。在流行地区,可能会出现某些特定物种和表现为主导的情况,而从热带医学转诊单位的角度来看,可能会观察到来自不同地理区域的更广泛的各种病例。
对西班牙一家热带医学转诊单位在 1995 年 1 月至 2008 年 6 月期间诊断的输入性利什曼病病例进行回顾性研究。
共诊断出 18 例病例:12 例皮肤利什曼病(CL)、4 例黏膜皮肤利什曼病(ML)和 2 例内脏利什曼病(VL)。有 2 例患者存在免疫抑制。大多数(9/12)旅行者CL 病例发生在新世界国家,采用五价锑剂治疗。3 例 ML 病例发生在新世界,其中 2 例最初采用五价锑剂治疗,2 例采用脂质体两性霉素 B(LAmB)治疗。对于所有 4 例 ML 病例,都需要改变药物选择和多次治疗疗程,其中 1 例仍对治疗有抵抗。2 例 VL 病例均在非洲获得,对 LAmB 治疗反应良好。
非流行地区的利什曼病管理对医生来说仍然是一个挑战。由于来自不同地理区域的移民和旅行者的病例多种多样,本系列说明了输入性利什曼病在表现、治疗选择和结局方面的巨大差异。我们认为这种疾病越来越常见,临床医生应该了解其正确管理的策略。